iBio (IBIO) Jefferies Global Healthcare Conference 2026 summary

Key strategic focus and portfolio development

• Portfolio targets obesity and related diseases post-GLP-1, aiming to address muscle loss, bone density, and weight rebound issues with a multi-product approach.

• Lead programs include IBIO-600 (myostatin, in clinic), IBIO-610 (activin E, filing in Australia by year-end), and a bispecific myostatin/activin A antibody for obesity and PH-HFpEF, with multiple clinical milestones expected over the next 18 months.

• Cash runway extends into Q2 2028, supporting advancement of clinical programs.

Scientific and clinical insights

• IBIO-600 combines myostatin and GDF11 inhibition, aiming for muscle preservation and fat reduction, with a long half-life to improve adherence.

• Activin E antibody targets fat-specific weight loss and inflammation, with potential as the first weight maintenance drug post-GLP-1 therapy.

• Bispecific antibody program aims to improve risk-benefit over ligand traps in PH-HFpEF by targeting disease-driving TGF-beta family members.

Differentiation and competitive positioning

• Antibody approach offers higher pathway inhibition than siRNA, potentially leading to greater efficacy, and allows for scalable manufacturing and established clinical trust.

• Unique antibody selectivity and extended half-life enable less frequent dosing (potentially twice a year), with flexibility for co-formulation with incretins.

• AI-driven antigen design and optimized screening strategies enabled successful development of neutralizing antibodies against complex targets like activin A.